abrdn Life Sciences Investors (NYSE:HQL) Short Interest Down 34.6% in December

abrdn Life Sciences Investors (NYSE:HQL) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 54,047 shares, a drop of 34.6% from the November 30th total of 82,698 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 122,447 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 122,447 shares, the short-interest ratio is currently 0.4 days. Approximately 0.2% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HQL. Geneos Wealth Management Inc. lifted its holdings in shares of abrdn Life Sciences Investors by 200.1% in the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after buying an additional 1,529 shares in the last quarter. Cornerstone Advisors LLC purchased a new stake in abrdn Life Sciences Investors in the 3rd quarter worth approximately $175,000. Stephens Inc. AR boosted its holdings in abrdn Life Sciences Investors by 9.8% in the 2nd quarter. Stephens Inc. AR now owns 21,231 shares of the company’s stock valued at $272,000 after purchasing an additional 1,895 shares during the period. Samalin Investment Counsel LLC boosted its holdings in abrdn Life Sciences Investors by 6.7% in the 2nd quarter. Samalin Investment Counsel LLC now owns 21,782 shares of the company’s stock valued at $279,000 after purchasing an additional 1,366 shares during the period. Finally, KPP Advisory Services LLC grew its position in shares of abrdn Life Sciences Investors by 7.7% during the 2nd quarter. KPP Advisory Services LLC now owns 23,555 shares of the company’s stock valued at $302,000 after purchasing an additional 1,681 shares in the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Price Performance

Shares of HQL stock opened at $17.25 on Friday. The company’s fifty day simple moving average is $17.02 and its two-hundred day simple moving average is $14.97. abrdn Life Sciences Investors has a 1 year low of $10.55 and a 1 year high of $17.80.

abrdn Life Sciences Investors Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 12th. Investors of record on Friday, November 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 11.6%. The ex-dividend date is Friday, November 21st. This is a positive change from abrdn Life Sciences Investors’s previous quarterly dividend of $0.42.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.